Compare Amylx Pharmaceuticals Inc (AMLX) vs Carlyle Group Inc (CG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Carlyle Group Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.45 (market cap $1.98B), while Carlyle Group Inc trades at $44.23 (market cap $16.09B). The key difference: Carlyle Group Inc is far larger — about 8.1× Amylx Pharmaceuticals Inc's market cap, and Carlyle Group Inc pays a 3.13% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | CG | |
|---|---|---|
Market Cap | $1.98B | $16.09B |
Sector | Health | Financials |
52-Week High | $18.70 | $69.35 |
52-Week Low | $7.64 | $40.52 |
Enterprise Value | $1.70B | — |
Dividend Yield | — | 3.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
CG trades at $44.71, up 1.2% today, with neutral technical signals and mixed earnings performance. The company reported Q1 2026 EPS of $0.89, missing expectations, but maintains a strong analyst consensus with a $60.33 price target. Recent developments include the acquisition of a majority stake in MAI Capital Management and the upcoming Q2 2026 earnings release on August 5, 2026.
The outlook is cautiously optimistic, supported by analyst bullishness and strategic acquisitions, but risks include volatile cash flows from operations and recent earnings misses. Investment opportunity lies in the significant upside to the consensus price target if execution improves, while downside risks stem from operational cash burn and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Carlyle Group Inc
The Carlyle Group is one of the world's largest alternative-asset managers, with $376.4 billion in total assets under management, including $259.6 billion in fee-earning AUM, at the end of June 2022. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure and natural resources funds (accounting for 41% of fee-earning AUM and 65% of base management fees during 2021), global credit (45% and 24%) and investment solutions (14% and 11%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving close to 2,700 active carry fund investors from 95 countries.
Read more on CG →
